Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus PHENERGAN VC.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
9-16 hours; prolonged in hepatic impairment.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination